1. Home
  2. MYGN vs ADNT Comparison

MYGN vs ADNT Comparison

Compare MYGN & ADNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MYGN
  • ADNT
  • Stock Information
  • Founded
  • MYGN 1991
  • ADNT 2016
  • Country
  • MYGN United States
  • ADNT Ireland
  • Employees
  • MYGN N/A
  • ADNT N/A
  • Industry
  • MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • ADNT Auto Parts:O.E.M.
  • Sector
  • MYGN Health Care
  • ADNT Consumer Discretionary
  • Exchange
  • MYGN Nasdaq
  • ADNT Nasdaq
  • Market Cap
  • MYGN 2.0B
  • ADNT 1.9B
  • IPO Year
  • MYGN 1995
  • ADNT N/A
  • Fundamental
  • Price
  • MYGN $15.72
  • ADNT $20.60
  • Analyst Decision
  • MYGN Buy
  • ADNT Hold
  • Analyst Count
  • MYGN 12
  • ADNT 9
  • Target Price
  • MYGN $27.64
  • ADNT $25.38
  • AVG Volume (30 Days)
  • MYGN 877.3K
  • ADNT 1.2M
  • Earning Date
  • MYGN 11-07-2024
  • ADNT 11-08-2024
  • Dividend Yield
  • MYGN N/A
  • ADNT N/A
  • EPS Growth
  • MYGN N/A
  • ADNT N/A
  • EPS
  • MYGN N/A
  • ADNT 0.20
  • Revenue
  • MYGN $823,600,000.00
  • ADNT $14,688,000,000.00
  • Revenue This Year
  • MYGN $13.85
  • ADNT $1.39
  • Revenue Next Year
  • MYGN $7.73
  • ADNT $0.83
  • P/E Ratio
  • MYGN N/A
  • ADNT $105.83
  • Revenue Growth
  • MYGN 12.15
  • ADNT N/A
  • 52 Week Low
  • MYGN $15.74
  • ADNT $19.30
  • 52 Week High
  • MYGN $29.30
  • ADNT $37.19
  • Technical
  • Relative Strength Index (RSI)
  • MYGN 17.62
  • ADNT 52.82
  • Support Level
  • MYGN $16.86
  • ADNT $19.30
  • Resistance Level
  • MYGN $19.60
  • ADNT $21.98
  • Average True Range (ATR)
  • MYGN 1.14
  • ADNT 0.85
  • MACD
  • MYGN -0.27
  • ADNT 0.12
  • Stochastic Oscillator
  • MYGN 1.27
  • ADNT 71.64

About MYGN Myriad Genetics Inc.

Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.

About ADNT Adient plc

Adient began trading Oct. 31, 2016, when Johnson Controls spun off its automotive experience segment into this new company. Adient is the leading seating supplier to the industry with about one third of the global market. Its share in China is now nearly 20%, down from about 45%, following the sale of its main joint venture there at the end of fiscal 2021. Unconsolidated seating revenue from joint ventures after factoring in the sale was about $3.8 billion in fiscal 2023 and consolidated China revenue was $1.4 billion. The company is headquartered in Ireland but has corporate offices in the Detroit area. Fiscal 2023 (Sept. 30 year-end) consolidated revenue, which excludes joint venture sales, was $15.4 billion and fiscal 2024 is forecast to about $14.6 billion.

Share on Social Networks: